Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers.
Tan
Kelvin H-V
KH
Hyman-Tylor
Pauline
P
Mulheran
Mike
M
Knox
Alan
A
Smyth
Alan
A
D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003550:Cystic Fibrosis / Q000150:complications; D003638:Deafness / Q000139:chemically induced; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects; D006113:United Kingdom
D000900:Anti-Bacterial Agents; D014031:Tobramycin